Who are Symtuza® (TAF/FTC/DRV/c)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): emtricitabine, darunavir/cobicistat, maraviroc.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/symtuza-taf-ftc-drv-c.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Symtuza® (TAF/FTC/DRV/c) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Symtuza® (TAF/FTC/DRV/c) (Symtuza® (TAF/FTC/DRV/c)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (NRTI/INSTI class with protease inhibitor). Area: Infectious Disease / Virology.

marketed Antiretroviral combination (NRTI/INSTI class with protease inhibitor) HIV reverse transcriptase, HIV protease, CYP3A4 Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Symtuza® (TAF/FTC/DRV/c) (Symtuza® (TAF/FTC/DRV/c)) — Fundacion SEIMC-GESIDA. Symtuza is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and protease to prevent viral replication.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Symtuza® (TAF/FTC/DRV/c) TARGET	Symtuza® (TAF/FTC/DRV/c)	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (NRTI/INSTI class with protease inhibitor)	HIV reverse transcriptase, HIV protease, CYP3A4
emtricitabine, darunavir/cobicistat, maraviroc	emtricitabine, darunavir/cobicistat, maraviroc	Giovanni Di Perri	marketed	Antiretroviral combination (NRTI + PI + pharmacokinetic booster + CCR5 antagonist)	HIV reverse transcriptase, HIV protease, CYP3A4, CCR5 co-receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (NRTI/INSTI class with protease inhibitor) class)

Fundacion SEIMC-GESIDA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Symtuza® (TAF/FTC/DRV/c) — Competitive Intelligence Brief. https://druglandscape.com/ci/symtuza-taf-ftc-drv-c. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab